Explore jobs
Find specific jobs
Explore careers
Explore professions
Best companies
Explore companies
Zippi applies for you, and finds you a job.
Aeglea BioTherapeutics received early financing of $12.0M on 2014-02-06.
| Series | Round size | Date |
|---|---|---|
| Series A | $12M | 02/2014 |
| Series B | $44M | 03/2015 |
| Investors | Security type |
|---|---|
| Novartis Venture Fund | Series A |
| UT Horizon Fund | Series A |
| Lilly Ventures | Series A |
| KBI Biopharma Inc | Series A |
| Novartis Venture Fund | Series B |
| UT Horizon Fund | Series B |
| Jennison Associates | Series B |
| Ally Bridge Group | Series B |
| Lilly Ventures | Series B |
| Venrock | Series B |
| OrbiMed Advisors | Series B |
| New Ground Ventures | Series B |
| RA Capital Management | Series B |
| Rock Springs Capital | Series B |
| Cowen Healthcare Investments | Series B |
Aeglea BioTherapeutics's top competitor, Global Blood Therapeutics, earned an annual revenue of $194.7M.
Aeglea BioTherapeutics's smallest competitor is Seelos Therapeutics with revenue of $375.0K last year.
| Company name | Average salary | Revenue | Employee size | Job openings |
|---|---|---|---|---|
| Zafgen | - | $6.5M | 20 | - |
| Allena Pharmaceuticals | - | $3.2M | 20 | - |
| Rallybio | - | $636,000 | 16 | - |
| Global Blood Therapeutics | - | $194.7M | 457 | - |
| Cyclerion | - | $2.0M | 175 | - |
| Salarius Pharmaceuticals | - | $5.2M | 5 | - |
| Lumena Pharmaceuticals | - | $1.3M | 17 | - |
| Lumos Pharma | - | $2.1M | 20 | - |
| Seelos Therapeutics | - | $375,000 | 10 | - |
| Viking Therapeutics | - | $28.1M | 15 | - |
Zippia gives an in-depth look into the details of Aeglea BioTherapeutics, including salaries, political affiliations, employee data, and more, in order to inform job seekers about Aeglea BioTherapeutics. The employee data is based on information from people who have self-reported their past or current employments at Aeglea BioTherapeutics. The data on this page is also based on data sources collected from public and open data sources on the Internet and other locations, as well as proprietary data we licensed from other companies. Sources of data may include, but are not limited to, the BLS, company filings, estimates based on those filings, H1B filings, and other public and private datasets. While we have made attempts to ensure that the information displayed are correct, Zippia is not responsible for any errors or omissions or for the results obtained from the use of this information. None of the information on this page has been provided or approved by Aeglea BioTherapeutics. The data presented on this page does not represent the view of Aeglea BioTherapeutics and its employees or that of Zippia.
Aeglea BioTherapeutics may also be known as or be related to AEGLEA BIOTHERAPEUTICS INC., Aeglea BioTherapeutics, Aeglea BioTherapeutics, Inc., Aeglea Biotherapeutics and Aeglea Biotherapeutics Inc.